Atossa to advance trial for COVID-19 nasal spray
A trial will be launched in Australia by Atossa Therapeutics to test the safety and tolerability of its experimental nasal spray AT-301 as a potential COVID-19 treatment after the study received clearance from Australian regulators. The nasal spray is designed to be used at home to decrease COVID-19 symptoms and decelerate the infection rate so the patient's immune system can combat the SARS-CoV-2 virus. Seeking Alpha (free registration) (8/3)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!